목적: We sought to investigate the association of diatetes medication including metformin and the recurrence of endometrial cancer. 방법: We have identified 56 patients with endometrial cancer (FIGO 2009)with diabetes mellitus who were treated atSeoul National University Hospital between 2000 and 2011 from the electronic medical record. A retrospective analysis was conducted comparing endometrial cancer patients with diabetes mellitus who used medication (based on medication review at the time of diagnosis) to those who did not use medication. Recurrence free survival(RFS) were evaluated using univariate and multivariate modeling. 결과: 11.5% (56/485) of endometrial cancer patients were diabetic, of whom ,only one patient (1/56) recurred comparing to endometrial cancer patients without diabetes(43/386) (p=0.04). Among them , 73% (41/56) used diabetes medication ;71%(29/41) used metformin, 63%(26/41) used sulfonilurea, 5%(2/41) used insulin,12%(5/41) used thiazolidinedion, 5% (2/41) used dipeptidyl peptidase-4, 12%(5/41) used alpha-glucosidase inhibitor. Age (p=0.12)and BMI(p=0.18) were similar between diabetes medication users and non users; including non-diabeties.92.5%(37/40) , 91.2%(407/446) of both groups had endometrioid histology(p=0.78). Stage, grade, and adjuvant therapy distributions were similar between two groups. Diabetes medication users had improved RFS than non-diabetes medication users in univariate analysis(p=0.039). However there was no significant difference between two groups in multivariate analysis after adjusting for age, stage, grade, histology and adjuvant treatment ; HR 1.033 (95% CI: 0.985?1.082, p=0.179) and HR =1.133(95% CI: 0.003?429.371, p =0.967) 결론: Diabetes medication use may not be associated with improved RFS. However, its role in modifying cancer recurrence remains unclear. Prospective clinical studies that capture each medication exposure prior to, during and post endometrial cancer treatment may help to define the significance of each medication to endometrial cancer upon cancer specific and overall health outcomes.